Navigation Links
Stemline Therapeutics Raises $12.5 Million
Date:4/9/2008

Proceeds to advance oncology therapeutics targeting cancer stem cells

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that it has completed a $12.5 million round of financing with healthcare funds managed by Pequot Capital Management, Inc.

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have consummated this transaction with a fund of this caliber. The capital provides us with significant runway to advance our clinical program, while continuing to build out our pipeline, discovery platform, and comprehensive IP estate. Moreover, this financing allows us to continue to strengthen our leadership position in the rapidly emerging cancer stem cell field."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. In addition, Stemline is developing a portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has also built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at http://www.stemline.com.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
5. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
6. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. Mercury Therapeutics Patents Filed
9. Cell Therapeutics, Inc. Announces Filing of Form 10-K
10. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 14 US Oncology, Inc., supporting the nation,s foremost cancer ... usoncology.com . In order to create an ... is part of a new branding effort to position ... cancer care. , , For the first time, ...
... April 14 Aaron,s Bridge presents Autism Research ... 2009, at The Embassy Suites Hotel and Convention ... conference will feature seminars devoted to educating doctors, ... Bryan Jepson, MD; Dan Rossignol, MD; and Doreen ...
... Bio-Optronics, Inc. and flexcipio s.a. ... and integrate Bio-Optronics, Clinical Conductor Clinical Trial Management ... (EDC) solution. This aligns the industry,s most comprehensive ... clinical research with the best tools to optimize ...
Cached Biology Technology:US Oncology Launches New Web Site 2US Oncology Launches New Web Site 3US Oncology Launches New Web Site 4US Oncology Launches New Web Site 5US Oncology Launches New Web Site 6Defeat Autism Now!(R) Regional Conference to be Held in Oklahoma June 13-14, 2009 2Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity 2
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... the marginal division of the striatum is also ... impact degree of substance P in the striatal ... Yu and his team, College of Biophotonics, South ... that substance P receptor, neurokinin 1 was highly ... of normal rats. Unilateral or bilateral injection of ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Biometrics Technology Market - Industry Analysis Size Share Growth ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has created a need for high level security in ... personnel authentication such as username and passwords, tokens etc. ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Iowa State University has led scientists to uncover how the ... A research team led by Gaya Amarasinghe, an assistant professor ... structure of a critical part of an Ebola protein known ... and his research team now know how VP35 is able ...
... -- University at Buffalo researchers are the first to ... bring athletes and others suffering with post-concussion syndrome (PCS) ... activities. In a paper published in the ... Medicine , the researchers report that a program of ...
... in the Gulf of Mexico, the seemingly sluggish red grouper ... But a new study led by researchers at The Florida ... ecosystem engineer. Most abundant along Florida,s west coast but ... from North Carolina to Brazil, the red grouper excavates and ...
Cached Biology News:Iowa State University researcher discovers Ebola's deadly secret 2UB specialized exercise regimen shown to relieve prolonged concussion symptoms 2UB specialized exercise regimen shown to relieve prolonged concussion symptoms 3New study reveals red grouper to be 'Frank Lloyd Wrights of the sea' 2New study reveals red grouper to be 'Frank Lloyd Wrights of the sea' 3
Rabbit polyclonal antibody to GluR2...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... be used to test the crossreactivity of ... that are commonly used as blocking reagents ... for 19 different protein preparations on a ... and species specificity, QC of purified antibodies, ...
... for 1,464 array sample elements. , , ,Includes: ... Blocker BSA in PBS (10X): 50 ml ... Buffered Saline: 8 packs , 10% Tween-20: 2 ... Enhancer: 2 x 25 ml , SuperSignal West Pico ...
Biology Products: